On Apr. 28, 2020, Sarepta Therapeutics announced the Company and the USAMRIID, the Department of Defense’s lead laboratory for medical biological defense research, have entered into a Cooperative Research and Development Agreement (CRADA).

The purpose of the CRADA is to jointly identify antisense oligonucleotides using Sarepta’s proprietary phosphorodiamidate morpholino oligomer platform with activity against SARS-CoV-2 for the potential treatment of COVID-19.